Insomnia Treatment Options: CBT-I, Sleep Aids, and Orexin Blockers

Chronic Insomnia Affects 10–15% of Adults

Chronic insomnia disorder — defined as difficulty initiating or maintaining sleep at least three nights per week for at least three months, causing daytime impairment — affects 10–15% of adults worldwide. It is the most common sleep complaint in primary care, yet its first-line treatment is not a pill. Cognitive behavioral therapy for insomnia (CBT-I) carries stronger long-term evidence than any sleep medication, produces durable improvements without dependence risk, and is now explicitly recommended over pharmacotherapy as first-line treatment by the American Academy of Sleep Medicine, the American College of Physicians, and the European Sleep Research Society.

CBT-I — Four Core Components

CBT-I is a structured 6–8 week therapy delivered individually or in group format, increasingly via validated digital platforms. It attacks the perpetuating factors of chronic insomnia rather than just suppressing symptoms. Four components form the core:

• Sleep restriction therapy: the most counterintuitive component. The patient's time in bed is curtailed to their estimated total sleep time (minimum 5–5.5 hours), building homeostatic sleep pressure. As sleep efficiency (time asleep / time in bed) exceeds 85% for five consecutive nights, the sleep window is extended by 15–30 minutes. This typically takes 2–4 weeks and involves transient sleepiness before improvement. It produces the largest effect size of any CBT-I component.
• Stimulus control: the bed is reconitioned as a cue exclusively for sleep and sex. Patients avoid lying awake in bed; if unable to sleep after approximately 20 minutes, they leave the bedroom and return only when sleepy. This extinguishes the learned arousal association with the bedroom that perpetuates insomnia.
• Cognitive restructuring: identifies and challenges unhelpful sleep-related beliefs ("I must get 8 hours or tomorrow will be ruined"; "I haven't slept properly in months") that increase pre-sleep anxiety. The catastrophizing cycle — fear → arousal → failed sleep → confirmation of fear — is the maintenance engine of chronic insomnia.
• Sleep hygiene education: the weakest component in isolation but supportive of others. Includes consistent wake time regardless of sleep quantity, limiting caffeine after noon, avoiding alcohol (which fragments sleep in the second half of the night despite initially sedating), and managing light exposure.

CBT-I vs Medication — Head-to-Head

Zolpidem — Widely Used, Increasingly Cautioned

Zolpidem (Ambien) is the most prescribed sleep medication in the United States, with approximately 9 million prescriptions annually. It is a non-benzodiazepine hypnotic that acts as a positive allosteric modulator of GABA-A receptors at the benzodiazepine binding site, selectively binding to alpha-1 subunit-containing receptors. This selectivity was intended to reduce anxiolytic and muscle-relaxant side effects while preserving hypnotic efficacy.

Next-day impairment is real. In 2013, the FDA required halving the recommended dose for women (from 10 mg to 5 mg) after data showed that women metabolize zolpidem more slowly, with blood levels remaining above the impaired driving threshold in 15% of women at 8 hours after a 10 mg dose. Complex sleep behaviors — sleepwalking, sleep-driving, sleep-eating — occur rarely but have been involved in serious accidents. A 2019 FDA boxed warning was added.

• Dementia signal: multiple observational studies, including a 2012 BMJ Open study of 5,000 patients, have associated long-term benzodiazepine and Z-drug (zolpidem) use with elevated dementia risk (hazard ratios of 1.5–1.7). Causality is unproven — reverse causality (early insomnia as prodrome of dementia) complicates interpretation.
• Rebound insomnia: abrupt discontinuation after sustained use causes 1–2 nights of severe rebound insomnia, reinforcing ongoing use.

Suvorexant — The Orexin Antagonist Approach

Suvorexant (Belsomra), FDA approved in August 2014, and lemborexant (Dayvigo, approved 2019) represent a mechanistically distinct approach. Rather than sedating by enhancing inhibitory GABA transmission, they block the orexin (hypocretin) system — the brain's primary wakefulness-promoting circuit. Dual orexin receptor antagonists (DORAs) block both OX1R and OX2R receptors, suppressing wakefulness drive and allowing sleep to emerge naturally.

Suvorexant 20 mg reduced subjective sleep onset latency by approximately 8 minutes and increased total sleep time by approximately 23 minutes versus placebo in phase 3 trials — modest but statistically significant and clinically meaningful gains. Next-day somnolence occurs in 7% of patients. No clinically significant rebound insomnia after discontinuation in trials. No evidence of physical dependence, though it is Schedule IV. The orexin approach is particularly appealing in older adults where benzodiazepine and Z-drug risks are highest.

Melatonin — Dose, Timing, and Realistic Expectations

Melatonin is a hormone produced by the pineal gland in response to darkness, signaling the circadian system that nighttime has arrived. It does not cause sleep directly — it advances or shifts the circadian timing system. Over-the-counter melatonin in the United States is sold in doses of 0.5–10 mg, but pharmacological doses of 0.5–1 mg are as effective as 5–10 mg doses for most applications, and high doses suppress endogenous melatonin production. The effective timing is 30–60 minutes before desired sleep time for insomnia, or 4–6 hours before habitual sleep time for phase-advancing delayed sleep-wake disorder. For jet lag, melatonin 0.5–3 mg taken at the destination's local bedtime for 2–4 nights after eastward travel is evidence-supported.

This article is for informational purposes only. Consult a qualified healthcare professional.